RxDoctor Payments Data

Gina Matacia, MD

Medical Oncology · Cincinnati, OHNPI 1891906459

Payments from drug & device makers

$4,641in general payments, 2019–2025

Across 79 payments — averaging $58.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$3K
  • Lilly USA, LLC$153
  • Novartis$145
  • Incyte Corporation$121
  • Pfizer$115
  • AstraZeneca$113
  • plus $718 from 22 others

What the payments were for

  • Speaking & faculty fees$2,66057%
  • Travel & lodging$251%
  • Food & beverage$1,95642%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,641 in reported general payments places this provider in the 30th percentile of 157 medical oncology providers in Ohio.

See all medical oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$82,984
Medicare patients
350
Services billed
982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KisqaliRibociclib Succinate20$298,511
IbrancePalbociclib17$251,622
BrukinsaZanubrutinib12$188,029
XareltoRivaroxaban83$95,970
CuvitruImmun Glob G(Igg)/Gly/Iga Ov5014$54,172
Imatinib Mesylate20$47,807
EliquisApixaban39$38,378
Anastrozole267$3,513
Erlotinib Hcl11$2,528
Exemestane11$1,589
Letrozole73$1,408
Tamoxifen Citrate34$999
Prochlorperazine Maleate29$414
Dexamethasone19$322
Alendronate Sodium37$216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisKisqali$145$298,51120 claims
PfizerIbrance, Eliquis$115$290,00056 claims
Takeda Pharmaceuticals U.S.A., Inc.Cuvitru$20$54,17214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 157 medical oncology providers in Ohio.

Other medical oncology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →